Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Among patients with colonrectal cancer, 5% were HER-2 positive, but the immunohistochemical
results were mostly HER-2 2 +, which did not meet the indications of HER-2 targeting drugs.
Disitamab Vedotin , which was listed in China last year, achieved similar results in HER-2 2+
and 3+, according to a clinical trial for breast cancer, suggesting that patients with
colonrectal cancer may benefit from it. Tislelizumab is a PD-1 monoclonal antibody, which has
been approved for a variety of tumors. It was reported that anti-HER-2 treatment can improve
the tumor immune microenvironment and improve the efficacy of immunotherapy. At the same
time, our previous studies showed that anti-PD-1 combined with Disitamab Vedotin can
significantly inhibit the growth of colon tumor in mice. Therefore, Disitamab Vedotin and
Tislelizumab were used in this study. This prospective clinical trial may bring new hope for
the treatment of HER-2 positive CRC patients.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University